Combination of Gemcitabine and Cisplatin as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
PURPOSE: The prognosis of patients with advanced non-small-cell lung cancer (NSCLC) is extremely poor. Many prospective randomized trials on patients with advanced NSCLC suggested systemic chemotherapy improves both the survival and quality of life. A phase II trial was conducted to evaluate the efficacy and safety profile of the combination chemotherapy of gemcitabine and cisplatin in advanced NSCLC. MATERIALS AND METHODS: Forty-four patients with locally advanced or metastatic NSCLC were enrolled. The patients received a cisplatin, 75 mg/m2, infusion over 30 minutes on days 1, followed by a gemcitabine, 1,250 mg/m2, infusion over 30 minutes on days 1 and 8 every 3 weeks. RESULTS: The median age of the patients was 64 years (range: 27~75). Forty-one patients were assessable for response and toxicity analyses. The overall response rate was 53.6%, but with no complete remissions. The median time to progression was 5.6 months (range: 1~15.4). The median survival was 14.2 months (95% confidence interval (CI), 13.8~22.5). A total of 179 cycles were administered, with a median of 4 cycles of chemotherapy, ranging from 2 to 9 cycles. The most common hematological toxicities were NCI grades 3/4 neutropenia (24%) and thrombocytopenia (7.8%). The most common non-hematological toxicity was fatigue (42.4%). There were no life-threatening toxicity or treatment related mortalities. The median duration of follow up was 9.4 months, ranging from 1.6 to 30.3 months. CONCLUSION: In this trial, the combination of gemcitabine and cisplatin showed significant activity, with acceptable and manageable toxicities as a first-line regimen for patients with advanced NSCLC. (Cancer Res Treat. 2004;36:173-177)
Abstract
PURPOSE: The prognosis of patients with advanced non-small-cell lung cancer (NSCLC) is extremely poor. Many prospective randomized trials on patients with advanced NSCLC suggested systemic chemotherapy improves both the survival and quality of life. A phase II trial was conducted to evaluate the efficacy and safety profile of the combination chemotherapy of gemcitabine and cisplatin in advanced NSCLC. MATERIALS AND METHODS: Forty-four patients with locally advanced or metastatic NSCLC were enrolled. The patients received a cisplatin, 75 mg/m2, infusion over 30 minutes on days 1, followed by a gemcitabine, 1,250 mg/m2, infusion over 30 minutes on days 1 and 8 every 3 weeks. RESULTS: The median age of the patients was 64 years (range: 27~75). Forty-one patients were assessable for response and toxicity analyses. The overall response rate was 53.6%, but with no complete remissions. The median time to progression was 5.6 months (range: 1~15.4). The median survival was 14.2 months (95% confidence interval (CI), 13.8~22.5). A total of 179 cycles were administered, with a median of 4 cycles of chemotherapy, ranging from 2 to 9 cycles. The most common hematological toxicities were NCI grades 3/4 neutropenia (24%) and thrombocytopenia (7.8%). The most common non-hematological toxicity was fatigue (42.4%). There were no life-threatening toxicity or treatment related mortalities. The median duration of follow up was 9.4 months, ranging from 1.6 to 30.3 months. CONCLUSION: In this trial, the combination of gemcitabine and cisplatin showed significant activity, with acceptable and manageable toxicities as a first-line regimen for patients with advanced NSCLC. (Cancer Res Treat. 2004;36:173-177)
참고문헌 (23)
- "Chemotherapy fornon-small-cell lung cancer", 99, pp.1326~1328 (1991)
- "Non small cell lungcancer, in De Vita VT Jr, Hellman S, Rosenberg SR eds:Cancer: Principles and Practice of Oncology", 1, pp.925~983 (2001), Lippincott-Raven
- "New chemotherapeutic agents prolongsurvival and improve quality of life in non-small cell lungcancer:A review of the literature and future directions", 4, pp.1087~1100 (1998)
- "supportive care in advanced non-small-celllung cancer results of a meta-analysis of the literature", pp.861~865
- "Chemotherapyin non-small cell lung cancer:A meta-analysis usingupdated data on individual patients from 52 randomisedclinical trials", 311, pp.899~909 (1995)
- "Chemotherapy for advancednon-small cell lung cancer:how much benefit is enough", 11, pp.1866~1872 (1993)
- "Mitomycin, ifosfamide, and cisplatin in unresectablenon-small-cell lung cancer: effects on survival and quality oflife", 17, pp.3188~3194 (1999)
- "Chemotherapy of lung cancer", 327, pp.1434~1441 (1992)
- "The treatment of non-small cell lung cancer:Current perspectives and controversies,future directions", 21, pp.49~59 (1994)
- "Comparison of four chemotherapy regimens foradvanced non-small-cell lung cancer", 346, pp.92~98 (2002)
- "Gemcitabine:A pharmacologic and clinical overview", 22, pp.176~183 (1999)
- "Phase II trials of single-agent activity of gemcitabinein patients with advanced non-small cell lung cancer:An overview", 6, pp.19~25 (1995)
- "Activity of gemcitabine in patients with non-small cell lung cancer: Amulticentre extended phase II study", 32, pp.243~248 (1996)
- "Efficacy ofgemcitabine chemotherapy in advanced non-small cell lungcancer (NSCLC) a phase II study", 31, pp.523~532 (1997)
- "Cisplatin-gemcitabine combination in advanced non-smallcelllung cancer: A phase II study", 15, pp.297~303 (1997)
- "Weeklygemcitabine and monthly cisplatin:Effective chemotherapy foradvanced non-small-cell lung cancer", 15, pp.744~749 (1997)
- "Anew cisplatin", gemcitabine schedule in locally advanced (IIIB)and metastatic (IV) non-small cell lung cancer: relationshipbetween dose-intensity and efficacy: A phase II study, 2002, pp.22, 3087~3092
- "Gemcitabine plus cisplatin in the treatment ofpatients with advanced non-small cell lung cancer:a phase IIstudy", 22, pp.3039~3043 (2002)
- "Phase I", II study of3-week cycle cisplatin-gemcitabine in advanced non-small celllung cancer, 2002, pp.32, 43~47
- "A phase II study of gemcitabine plus cisplatin inpatients with advanced non-small cell lung cancer:clinicaloutcomes and quality of life", 351, pp.73~79 (2002)
- "A three-week schedule of gemcitabine-cisplatin in advancednon-small-cell lung cancer with two different cisplatin doselevels: a phase II randomized trial", 11, pp.1295~1300 (2000)
- "3-week-scheduledcombination chemotherapy of gemcitabine and cisplatin inpatients with advanced NSCLC", 66, pp.58~66 (2004)
- "Three-arm randomized study of twocisplatin-based regimens and paclitaxel plus gemcitabine inadvanced non-small-cell lung cancer a phase III trial of theEuropean Organization for Research and Treatment of CancerLung Cancer Group-EORTC 08975", 21, pp.3909~3917 (2003)